Allogene Therapeutics Inc. [NASDAQ: ALLO] plunged by -$0.45 during the normal trading session on Thursday and reaching a high of $25.35 during the day while it closed the day at $24.75. The company report on May 20, 2021 that Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences.
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced that management plans to participate in five upcoming virtual investor conferences.
Cowen’s 2nd Annual Virtual Oncology Innovation Summit Friday, May 21, 202110:20AM PT/1:20PM ET.
Allogene Therapeutics Inc. stock has also loss -7.82% of its value over the past 7 days. However, ALLO stock has declined by -28.69% in the 3 months of the year. Over the past six months meanwhile, it has lost -20.44% and lost -1.94% year-on date.
The market cap for ALLO stock reached $3.61 billion, with 132.16 million shares outstanding and 72.50 million shares in the current float. Compared to the average trading volume of 1.12M shares, ALLO reached a trading volume of 3072977 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Allogene Therapeutics Inc. [ALLO]:
Truist have made an estimate for Allogene Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 20, 2021. While these analysts kept the previous recommendation, B. Riley Securities raised their target price to Buy. The new note on the price target was released on May 14, 2021, representing the official price target for Allogene Therapeutics Inc. stock. Previously, the target price had yet another raise from $33 to $43, while Stifel kept a Buy rating on ALLO stock.
The Average True Range (ATR) for Allogene Therapeutics Inc. is set at 1.76, with the Price to Sales ratio for ALLO stock in the period of the last 12 months amounting to 94.38. The Price to Book ratio for the last quarter was 3.06, with the Price to Cash per share for the same quarter was set at 4.79.
ALLO stock trade performance evaluation
Allogene Therapeutics Inc. [ALLO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.82. With this latest performance, ALLO shares dropped by -29.10% in over the last four-week period, additionally sinking by -20.44% over the last 6 months – not to mention a drop of -46.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALLO stock in for the last two-week period is set at 32.54, with the RSI for the last a single of trading hit 29.44, and the three-weeks RSI is set at 35.44 for Allogene Therapeutics Inc. [ALLO]. The present Moving Average for the last 50 days of trading for this stock 31.50, while it was recorded at 25.18 for the last single week of trading, and 33.07 for the last 200 days.
Allogene Therapeutics Inc. [ALLO]: An insightful look at the core fundamentals
Return on Total Capital for ALLO is now -28.48, given the latest momentum, and Return on Invested Capital for the company is -27.64. Return on Equity for this stock declined to -29.29, with Return on Assets sitting at -25.72. When it comes to the capital structure of this company, Allogene Therapeutics Inc. [ALLO] has a Total Debt to Total Equity ratio set at 4.98. Additionally, ALLO Total Debt to Total Capital is recorded at 4.75, with Total Debt to Total Assets ending up at 4.38. Long-Term Debt to Equity for the company is recorded at 4.71, with the Long-Term Debt to Total Capital now at 4.48.
Reflecting on the efficiency of the workforce at the company, Allogene Therapeutics Inc. [ALLO] managed to generate an average of -$944,230 per employee.Allogene Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.10 and a Current Ratio set at 13.10.
Earnings per share (EPS) analysis for Allogene Therapeutics Inc. [ALLO] stock
With the latest financial reports released by the company, Allogene Therapeutics Inc. posted -0.53/share EPS, while the average EPS was predicted by analysts to be reported at -0.54/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 1.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Allogene Therapeutics Inc. go to 1.00%.
Allogene Therapeutics Inc. [ALLO]: Insider Ownership positions
There are presently around $2,269 million, or 63.20% of ALLO stock, in the hands of institutional investors. The top three institutional holders of ALLO stocks are: TPG GROUP HOLDINGS (SBS) ADVISORS, INC. with ownership of 18,716,306, which is approximately 0% of the company’s market cap and around 2.30% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 12,664,013 shares of the stock with an approximate value of $319.13 million in ALLO stocks shares; and CAPITAL INTERNATIONAL INVESTORS, currently with $166.3 million in ALLO stock with ownership of nearly -7.424% of the company’s market capitalization.
Positions in Allogene Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 79 institutional holders increased their position in Allogene Therapeutics Inc. [NASDAQ:ALLO] by around 5,125,676 shares. Additionally, 91 investors decreased positions by around 6,626,515 shares, while 29 investors held positions by with 78,301,238 shares. The mentioned changes placed institutional holdings at 90,053,429 shares, according to the latest SEC report filing. ALLO stock had 32 new institutional investments in for a total of 2,906,498 shares, while 28 institutional investors sold positions of 1,784,121 shares during the same period.